Andy Sheldon Named CEO of the Year by Vaccine Industry Excellence Awards at the World Vaccine Congress
Medicago announced that Chief Executive Officer Andy Sheldon was named "CEO of the Year" at the recently held World Vaccine Congress in Washington, D.C. The Vaccine Industry Excellence (ViE) Awards recognize the outstanding achievements of vaccine practitioners and stakeholders across the global industry.
TSO3 announces $7.8 million bought private placement
TSO3 is pleased to announce it has entered into an agreement with a syndicate of underwriters led by Desjardins Capital Markets and Canaccord Genuity Corporation and including Byron Capital Markets, pursuant to which the Underwriters have agreed to purchase, on a bought deal private placement basis, 6,000,000 units in the capital of TSO3 at the price of $1.30 per Unit for aggregate gross proceeds to TSO3 of $7,800,000.
Medicago Announces Investment in Quebec City Pilot Production Facility
Medicago announces it plans to invest approximately $4 million to enhance the capacity of the pilot production facility located in Quebec City. The Company expects this investment to accelerate preclinical and clinical development timelines of future product candidates. This new investment includes capital expenditures and labour costs, as well as preclinical studies for a rabies vaccine and other products.
FDA Approves Progensa® PCA3 Assay First Urine‐Based Molecular Test to Help Determine Need for Repeat Prostate Biopsies
DiagnoCure, a Quebec life sciences company that develops and commercializes high‐value cancer diagnostic tests, announced today that the US Food and Drug Administration (FDA) has approved Gen‐Probe's PROGENSA® PCA3 assay, the first molecular test to help determine the need for repeat prostate biopsies in men who have had a previous negative biopsy.
Lucas Meyer Cosmetics Acquires innoVactiv's Cosmetic Ingredient Portfolio
Lucas Meyer Cosmetics, the business unit of the Unipex Group and leader in the field of innovative active ingredients, functional ingredients, and delivery systems for the cosmetics industry, is acquiring the cosmetic ingredients portfolio from innoVactiv inc. that it has been marketing worldwide.
Medicago Inc. and Mitsubishi Tanabe Pharma Corporation Enter into a Strategic Alliance to Develop New Vaccines
Medicago announces the establishment of a strategic alliance
with Mitsubishi Tanabe Pharma Corporation (MTPC) through the
execution of a Master Research Collaboration Agreement. The
objectives are to develop and commercialize at least three new
vaccines with MTPC who will provide funding for all research and
development costs. In exchange for granting licensing rights,
Medicago will be entitled to receive upfront and milestone payments
as well as royalties for each product to be developed under this